|
**Overview**: Pap Smear Conventional Panel**Introduction**: The Pap Smear Conventional Panel is a diagnostic tool designed to screen for cervical cancer using cervical swab samples. In India, cervical cancer is the second most common cancer in women (~120,000 cases/year), largely preventable with screening; Pap smear detects precancerous lesions (CIN) caused by HPV. High burden from under-screening in rural/low-SES women, limited cytology labs, delayed detection leading to advanced disease and mortality. Per gynecology practices aligned with ICMR, FOGSI, and National Cancer Control Programme guidelines, the test employs conventional microscopy for cytology over 1-2 days with high specificity for abnormal cells, valuable for opportunistic screening. This diagnostic falls under cervical screening and targets women aged 25-65 or with risk factors, addressing accurate detection to guide colposcopy/biopsy or HPV vaccination. With elevated morbidity due to under-screening, the test supports public health efforts by enabling precise identification and reducing cervical cancer burden. Its swab-based approach ensures reliable detection.**Other Names**: Pap Conv Pnl.**FDA Status**: FDA approved, CLIA certified for histopathology, compliant with 2025 standards.**Historical Milestone**: Pap smear standard since 1940s; in India, key in national screening programs.**Purpose**: The test assesses 3 parameters including cervical cytology to guide cervical cancer screening, detect abnormal cells, inform further evaluation.**Test Parameters**: 1. Cervical Cytology, 2. HPV Status, 3. Cell Morphology.**Pretest Condition**: No fasting required; women should avoid douching/intercourse 48 hours prior.**Specimen**: 1 cervical swab in liquid-based medium, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve cell integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate processing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for cytology).**Medical History**: Patients should provide details on menstrual history, bleeding, discharge, HPV vaccination, prior Pap results.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected cervical changes including cancer, benefits of early detection, and minimal discomfort from swab.**Procedural Considerations**: The test involves sample processing using microscopy by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or inadequate sampling can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal cytology indicates precancerous changes, necessitating specialist input. Normal may require follow-up per guidelines.**Specialist Consultation**: Gynecologists should be consulted for management.**Additional Supporting Tests**: HPV DNA test, colposcopy for confirmation.**Test Limitations**: Conventional less sensitive than liquid-based; comprehensive approach required.**References**: Indian Journal of Gynecology Oncology 2024, Cervical Screening Studies India 2023. |
